IRIS
ROSSETTI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.272
NA - Nord America 4.812
AS - Asia 2.441
SA - Sud America 452
AF - Africa 173
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.173
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.713
IT - Italia 1.125
RU - Federazione Russa 1.109
GB - Regno Unito 959
SG - Singapore 740
CN - Cina 607
IE - Irlanda 603
VN - Vietnam 379
BR - Brasile 365
SE - Svezia 306
FR - Francia 298
DE - Germania 284
HK - Hong Kong 239
UA - Ucraina 157
FI - Finlandia 140
IN - India 100
ZA - Sudafrica 84
NL - Olanda 70
ES - Italia 58
CA - Canada 55
KR - Corea 47
IR - Iran 45
BD - Bangladesh 41
PL - Polonia 40
TR - Turchia 38
MX - Messico 30
IQ - Iraq 28
AR - Argentina 25
PK - Pakistan 23
AT - Austria 22
CZ - Repubblica Ceca 20
JP - Giappone 20
PH - Filippine 18
BE - Belgio 15
CO - Colombia 15
NG - Nigeria 15
AU - Australia 14
CI - Costa d'Avorio 13
EG - Egitto 13
CH - Svizzera 12
ID - Indonesia 11
KE - Kenya 11
VE - Venezuela 11
EC - Ecuador 10
MA - Marocco 10
CL - Cile 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
DK - Danimarca 8
LT - Lituania 8
NP - Nepal 8
UZ - Uzbekistan 8
IL - Israele 7
JO - Giordania 6
PT - Portogallo 6
PY - Paraguay 6
CY - Cipro 5
ET - Etiopia 5
LV - Lettonia 5
MY - Malesia 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
AZ - Azerbaigian 4
DZ - Algeria 4
EU - Europa 4
KG - Kirghizistan 4
LK - Sri Lanka 4
MN - Mongolia 4
PS - Palestinian Territory 4
SN - Senegal 4
TH - Thailandia 4
UY - Uruguay 4
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
JM - Giamaica 3
LB - Libano 3
NZ - Nuova Zelanda 3
QA - Qatar 3
RO - Romania 3
AO - Angola 2
BS - Bahamas 2
BW - Botswana 2
CG - Congo 2
CR - Costa Rica 2
EE - Estonia 2
HR - Croazia 2
IM - Isola di Man 2
LU - Lussemburgo 2
NO - Norvegia 2
OM - Oman 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
Totale 13.154
Salva come PNG Salva come JPEG
Città #
Dallas 860
Southend 770
Dublin 587
Singapore 432
Ashburn 366
Chandler 326
Moscow 323
Fairfield 309
Santa Clara 238
Hong Kong 211
Beijing 201
Siena 169
San Jose 161
Menlo Park 146
Woodbridge 121
Seattle 120
Ho Chi Minh City 114
Jacksonville 114
Milan 114
Cambridge 111
Ann Arbor 108
Houston 105
Wilmington 102
Munich 99
Princeton 91
Los Angeles 88
New York 81
Council Bluffs 80
Hanoi 78
Rome 78
Helsinki 74
Johannesburg 74
Lauterbourg 67
Florence 65
Dong Ket 55
Hefei 52
The Dalles 50
Nanjing 46
Orem 46
Seoul 43
São Paulo 41
Málaga 37
Buffalo 33
Chicago 33
Boardman 31
London 30
Turku 30
Shanghai 27
Warsaw 26
Dearborn 24
Nuremberg 24
Chennai 23
San Mateo 23
Frankfurt am Main 22
San Diego 22
Montreal 19
Nottingham 18
Stockholm 18
Denver 17
Lappeenranta 17
Da Nang 16
Tehran 16
Toronto 16
Catania 15
Fremont 15
Perugia 15
Tokyo 15
Izmir 14
Phoenix 14
Redondo Beach 14
Rio de Janeiro 14
Abidjan 13
Abuja 13
Amsterdam 13
Atlanta 13
Brussels 13
Karaj 13
Paris 13
Vienna 13
Baghdad 12
Brescia 12
Düsseldorf 12
Haiphong 12
Athens 11
Bengaluru 11
Columbus 11
Lancaster 11
Portsmouth 11
Prague 11
Brooklyn 10
Comun Nuovo 10
Guangzhou 10
Horsham 10
Mumbai 10
Shenyang 10
Tianjin 10
Coventry 9
Jiaxing 9
Kowloon 9
Nanchang 9
Totale 8.278
Salva come PNG Salva come JPEG
Nome #
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 574
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 565
Genetic mechanisms of critical illness in COVID-19 409
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 387
An explainable model of host genetic interactions linked to COVID-19 severity 365
Antirheumatic agents in covid-19: is IL-6 the right target? 354
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 342
null 320
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 311
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 303
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 293
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 292
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 282
HCMV infection in renal transplant recipients: a retrospective cohort study 279
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 277
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 270
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 268
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 266
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 265
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 257
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 248
Serial KL-6 measurements in COVID-19 patients 246
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 245
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 244
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 240
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 235
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 231
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 227
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 211
Use of Miltefosine in a Patient With Mucosal Leishmaniasis and HIV-coinfection: A Challenge in Long-Term Management 209
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 206
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 204
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 202
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 199
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 187
Which screening for Leishmania infantum in asymptomatic blood donors? 178
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 176
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 174
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 174
Gestione clinica di effetti collaterali multipli in un paziente con epatite cronica da HCV in trattamento con terapia triplice comprendente telaprevir 172
Il ruolo dell'infezione da CMV e del suo monitoraggio attivo nella nuova era dei trapianti di rene: risultati di una coorte completa 170
Infezione da Mycobacterium marinum: le difficoltà diagnostiche e terapeutiche di un caso raro 166
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 163
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 160
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 155
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 153
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 136
Laboratory diagnosis of Mycoplasma pneumoniae infections: data analysis from clinical practice 130
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019 125
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 124
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort 108
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 107
The Uprise of Human Leishmaniasis in Tuscany, Central Italy: Clinical and Epidemiological Data from a Multicenter Study 106
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 106
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic 100
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 99
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 89
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 80
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients 79
Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial 79
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 70
null 14
Mapping the human genetic architecture of COVID-19 5
Totale 13.411
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.585
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.585
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021294 0 0 0 0 0 0 0 0 0 96 87 111
2021/2022977 84 94 45 95 46 36 53 51 76 89 104 204
2022/20231.308 61 141 162 133 98 216 76 126 122 72 61 40
2023/20241.262 43 48 110 76 70 297 347 59 10 52 56 94
2024/20252.102 84 94 277 131 272 153 123 112 184 103 209 360
2025/20264.957 331 637 720 700 1.165 182 582 159 206 275 0 0
Totale 13.411